TABLE 3.
Correlation Between 124I-Evuzamitide Uptake and Direct and Indirect Markers of Amyloid Burden, Functional Status and Quality of Life
| Correlation With 124I–Evuzamitide LV %ID | P Value | |
|---|---|---|
| Quality of life and functional status, n = 36 | ||
| NYHA functional class | 0.47 (0.16 to 0.70) | 0.004 |
| MLWHFQ total score | 0.59 (0.32 to 0.78) | <0.001 |
| KCCQ overall score | −0.62 (−0.79 to −0.36) | <0.001 |
| SF-36 physical summary T-score | −0.50 (−0.72 to −0.20) | 0.002 |
| SF-36 mental summary T score | −0.41 (−0.65 to −0.08) | 0.014 |
| 6-min walk test distance, m | −0.13 (−0.45 to 0.22) | 0.458 |
|
| ||
| Laboratory tests, n = 36 | ||
| Troponin T, ng/mL | 0.73 (0.53 to 0.86) | <0.001 |
| NT-proBNP, pg/mL | 0.72 (0.50 to 0.85) | <0.001 |
|
| ||
| Echocardiogram, n = 23 | ||
| Interventricular septum, mm | 0.78 (0.53 to 0.90) | <0.001 |
| LV mass index, g/m2 | 0.70 (0.39 to 0.87) | <0.001 |
| LV ejection fraction, % | −0.37 (−0.68 to 0.06) | 0.084 |
| LV MCF, % | −0.66 (−0.85 to −0.33) | <0.001 |
| LV GLS, % | 0.54 (0.10 to 0.80) | 0.017 |
|
| ||
| CMR, n = 13 | ||
| Interventricular septum, mm | 0.58 (−0.10 to 0.89) | 0.079 |
| LV mass index, g/m2 | 0.82 (0.45 to 0.95) | 0.001 |
| LV ejection fraction, % | −0.32 (−0.75 to 0.30) | 0.289 |
| LV MCF, % | −0.62 (−0.88 to −0.04) | 0.033 |
| LV extracellular volume, % | 0.51 (−0.11 to 0.84) | 0.092 |
|
| ||
| Radionuclide imaging | ||
| 99mTc-PYP SPECT grade, n = 11 | 0.45 (−0.23 to 0.83) | 0.167 |
| 18F-florbetapir LV %ID, n = 23 | 0.50 (0.10 to 0.76) | 0.015 |
Values are Spearman’s ρ (95% CI) unless otherwise indicated. Correlations among 124I-evuzamitide LV %ID and quality of life, functional status, and laboratory tests were assessed in participants undergoing 124I-evuzamitide PET/CT (12 AL-CMP, 12 ATTRwt-CMP, and 12 control subjects). Correlations with echocardiogram, CMR and radionuclide imaging were evaluated in participants with amyloid cardiomyopathy and available imaging metrics.